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ABSTRACT. A series of novel hydrogen peroxide sensitive prodrugs of methotrexate (MTX) and 
aminopterin (AMT) were synthesized and evaluated for therapeutic efficacy in mice with collagen 
induced arthritis (CIA) as a model of chronic rheumatoid arthritis (RA). The prodrug strategy 
selected is based on ROS-labile 4-methylphenylboronic acid promoieties linked to the drugs via a 
carbamate linkage or a direct C‒N bond. Activation under patho-physiological concentrations of 
H2O2 proved to be effective and prodrug candidates were selected in agreement with relevant in 
vitro physicochemical and pharmacokinetic assays. Selected candidates showed moderate to good 
solubility, high chemical and enzymatic stability, and therapeutic efficacy comparable to the parent 
drugs in the CIA model. Importantly, the prodrugs displayed the expected safer toxicity profile 
and increased therapeutic window compared to MTX and AMT while maintaining a comparable 
therapeutic efficacy, which is highly encouraging for future use in RA patients. 
 
KEYWORDS: aminopterin, collagen-induced arthritis, hydrogen peroxide, methotrexate, 
phenylboronic acid, prodrug, rheumatoid arthritis.  
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INTRODUCTION 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic destructive 
synovitis and is associated with progressive disability, systemic difficulties, premature death, and 
socioeconomic costs.1 The cause of RA remains unknown and currently no cure for the disease 
exists. Several studies have estimated the prevalence of RA to range between 0.5% to 1% of the 
adult population in developed countries, with a 3 to 1 female to male ratio.2  
Aminopterin (1, AMT, Figure 1), an anti-folate drug initially developed for treatment of 
leukemia, was tested for RA treatment in 1951.3,4 Complex manufacturing,5 unpredictable 
toxicities,6–9 and low therapeutic index8,10 led scientist to develop methotrexate (2, MTX,  
Figure 1), as an alternative antifolate for cancer therapy which later showed anti-arthritic properties 
as a disease modifying anti-rheumatic drug (DMARD). In 1988, low-dose MTX  
(LD-MTX, <30 mg in weekly pulses) was approved by the FDA for the treatment of RA and has 
remained the standard of care since.11,12 Although efficacious, the mechanisms that govern the 
anti-inflammatory and immunosuppressive effects of MTX in rheumatic diseases are still not 
completely understood.13 Furthermore, the population of patients that will be responsive to an 
MTX regiment cannot be reliably predicted before initiating treatment.14 Adverse effects and low 
efficacy of LD-MTX in RA are the predominant reasons for discontinuation of treatment. Side 
effects are usually mild, self-limiting, and/or preventable, but a subset of patients suffers from 
severe side-effects. Toxicities including anemia, neutropenia, stomatitis, oral ulcers, lethargy, 
fatigue, nodulosis, hepatic and pulmonary fibrosis, as well as renal insufficiency are associated to 
this drug. 15–18 Additionally, progressive drug tolerance of disease, high patient variability, and 
pharmacokinetic inadequacies of LD-MTX suggest the need of more efficient and safer RA 
therapies.  
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Figure 1. Chemical structure of aminopterin (AMT, 1) and methotrexate (MTX, 2) 
 
Prodrugs are chemically modified drugs that have either no or greatly decreased activity 
compared to the parent drug. Upon administration, prodrugs are activated in the body through 
chemical and/or enzymatic transformation into the pharmaceutically active moiety.19 
Approximately 20% of drugs approved since 2000 are prodrugs,20 mostly designed to minimize 
and/or overcome unacceptable absorption, distribution, metabolism, excretion, and toxicity 
(ADMET) properties of the native drug.21 Several prodrugs, drug conjugates, and drug delivery 
systems for methotrexate have been reported in the literature but none of them have been approved 
for clinical use yet. 22–33 
Reactive oxygen species (ROS), like H2O2, HO•, O2-, produced by phagocytes and neutrophils,34 
have important physiological roles in priming the immune system.35,36  Increasing evidence from 
different studies supports the relation between oxidative stress and the pathogenesis of 
inflammation and rheumatoid arthritis.37,38 In RA, oxidative stress has been described as an 
important mechanism in the pathogenesis of destructive proliferative synovitis. Under pathological 
inflammatory conditions, the extracellular concentration of H2O2, the most stable ROS, has been 
determined to be up to a 100-fold higher compared to healthy tissue, reaching concentrations as 
high as 1.0 mM.39–44 The presence of increased concentrations of H2O2 in the inflammatory 
environment can serve as the stimulus for prodrug activation in site-selective drug delivery 
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systems. Phenylboronic acids and esters,45–48 phenylsulfonate esters,49 thiazolidinones,44 N-(2,5-
dihydroxyphenyl)acetamides,50 and α-boryl ethers, carbonates, and acetals51 have been reported as 
useful structural motifs for hydrogen peroxide activatable prodrugs and imaging, but studies have 
mainly focused on their applications in oncology. 
Here we propose a new approach to RA therapy based on the use of phenylboronic acid-
containing prodrugs that are inactive until activated locally in the inflammatory tissue. This 
mechanism secures that the biological activity is limited to regions of inflammation to facilitate a 
safer toxicity profile compared to AMT and MTX, and a more effective treatment due to the 
expected localization and accumulation in the target tissue. We have designed and synthesized a 
series of MTX and AMT prodrugs that are activated by disease- and tissue-specific factors like 
H2O2. Their physicochemical, pharmacokinetic, and drug-like properties have been evaluated in 
in vitro assays. Additionally, their in vivo efficacy and preliminary toxicity in the murine collagen-
induced arthritis model (CIA) was assessed. 
RESULTS AND DISCUSSION 
Synthesis of prodrugs. The pinacolates 4b and 4c were synthesized from the corresponding  
4-hydroxymethylphenyl boronic acids 3b and 3c via condensation with pinacol (Scheme 1). 
Subsequently, the chloroformates 5a‒c were achieved by reaction of 3a‒c with phosgene. In 
parallel, the MTX core structure was synthesized starting with bromination of 2,4-diamino-6-
(hydroxymethyl)pteridine hydrochloride (6·HCl) and alkylation of 4-methylaminobenzoic acid to 
form the pteoric acid 7, following the procedure described by Kralovej et al.52 Amide coupling of 
7 with dimethylglutamate hydrochloride 9·HCl, synthesized from glutamic acid 8, provided 
methotrexate dimethylester 10. Finally, coupling between 10 and 5a-c formed the desired prodrugs 
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11‒13 after hydrolysis of the pinacolate with HCl in a mixture of H2O/MeCN. The use of DMAP 
in the coupling step was crucial for the progression of the reaction. Compounds 11‒13 represent a 
set of MTX prodrugs in which the promoiety is linked to MTX via a carbamate linkage. The 
promoiety contains different ortho-substituents (H, F or Me) in order to investigate the effect of 
modifying the steric and electronic environment around the boronic acid on reactivity towards 
H2O2 . Furthermore, the carboxylic acids of MTX were also masked as methyl esters. 
Scheme 1. Synthesis of MTX prodrugs 11‒13a 
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aReagents and conditions: (a) pinacol, THF, reflux, 16 h (>94%). (b) COCl2 (20% in toluene), 
dioxane, 21 oC, 20 h (>95%). (c) NaOH, H2O. (d) PPh3Br2, DMA, 21 oC, 20 h, then  
4-methylaminobenzoic acid, DIPEA, 3 days (77%). (e) PyBOP, Et3N, DMF, 21 oC, 30 min, then 
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9·HCl (86%). (f) MeOH, SOCl2, 21 oC, 4 days (>95%). (g) 5a‒c, DIPEA, DMAP, CH2Cl2, 21 oC, 
5 h. (h) HCl in H2O/MeCN, 21 oC, 16 h (27‒32%). 
Efforts aiming for hydrolysis of the methyl esters in 11‒13 using standard conditions based on 
alkaline hydrolysis with NaOH53 or LiOH,54 LiI in pyridine,55 or enzymatic hydrolysis using a 
polymer supported lipase from Candida antarctica56 were unsuccessful. Therefore a new synthetic 
strategy was proposed (see Scheme 2).  
Starting from MTX, the synthesis of the corresponding PMB protected intermediate 14 was 
achieved. Following the same procedure described for the synthesis of 11‒13, coupling between 
5a and 14 afforded 15, which was hydrolyzed to form the corresponding boronic acid 16. Lastly, 
PMB deprotection under acidic conditions afforded the prodrug 17.  
Scheme 2. Synthesis of MTX prodrug 17a 
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aReagents and conditions: (a) PMBCl, 1,1,3,3-tetramethylguanidine, CH2Cl2, 21 oC, 16 h (35%). 
(b) 5a, DIPEA, DMAP, CH2Cl2, 21 oC, 5 h (73%). (c) HCl in H2O/MeCN, 21 oC, 20 h (31%). (d) 
5% TFA in CH2Cl2, 21 oC, 30 min (54%). 
Cbz protection of 4-aminobenzoic acid (18) formed 19 and two-step coupling with 9·HCl 
produced 20. Hydrogenolysis of 20 afforded 21 in high yields, which was subjected to reductive 
alkylation with 4-formylphenylboronic acid to give 22. Alkylation of 22 with 6-(bromomethyl)-
2,4-pteridinediamine hydrobromide (23·HBr) formed the first AMT prodrug 24. The concentration 
of the reaction was critical to obtain a reasonable yield, as previously published by Montgomery 
et al.57 for similar substrates. The last step consisted of alkaline hydrolysis of 24 to form the second 
AMT prodrug 25. These compounds represent the proposed set of phenylboronic acid-based AMT 
prodrugs in which the promoiety is attached to the secondary aniline group, bearing methylester 
protected (24) or free carboxylic acids (25). 
Scheme 3. Synthesis of AMT prodrugs 24 and 25a 
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aReagents and conditions: (a) CbzCl, NaHCO3, H2O/dioxane, 21 oC, 2 h (89%). (b) SOCl2, DMF, 
CH2Cl2, reflux, 24 h. (c) 9·HCl, Et3N, CH2Cl2, 21 oC, 2 h (>95%). (d) H2, Pd/C, MeOH, 21oC, 12 
h. (e) HCl in Et2O (>95%). (f) NaBH4, MeOH, 21 oC, 24 h (67%). (g) DMA, 55 oC, 3 days (43%). 
(h) NaOH, H2O, 21oC, 5 min (40%). 
Activation of prodrugs. For a proof-of-principle of the prodrug strategy, a study on the 
activation of 11‒13, 17, 24, and 25 under patho-physiological concentrations of H2O2 was 
performed. The experiment consisted on the incubation of test compounds in a 30% DMSO in 
PBS mixture at a concentration of 50 µM and H2O2 concentration found in inflammatory tissue 
(0.5 mM, 10 equiv.) at 37 oC. The activation was followed by RP-UPLC-MS (see Figure S1 and 
Figure S2 for examples on prodrug  17 and 25 chromatograms, respectively). Negative controls 
(no H2O2 addition) were performed in parallel (Figure S3). The rationale behind the substitution 
of a hydrogen atom in the ortho-position of the phenylboronic acid promoiety by a methyl group 
or a fluorine atom was the reactivity towards oxidative deboronation. Interestingly, prodrugs  
11‒13 were activated and released 10 within less than 3 h (>95% conversion by UPLC-MS), 
therefore no effects on the reaction rate by ortho-substituents was observed under the conditions 
tested (Figure 2, left). Furthermore, 17 was activated within the same time frame, releasing 
exclusively MTX, with no significant difference compared to 11‒13. The plot of the formation of 
prodrug activation products versus time can be found in the SI (Figure S4). Moreover, a 
concentration dependent release of drug was observed as determined in an activation assay using 
different concentrations of H2O2 (see Figure S5). 
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Figure 2. Activation of MTX prodrugs 11‒13 and 17 (left), and AMT-prodrugs 24 and 25, as well 
as formation and disappearance of intermediates 26 and 27 (right). The experiment was carried out 
at a compound concentration of 50 µM and 0.5 mM H2O2 (10 equiv.) in a mixture of 30% DMSO 
in PBS at 37 oC. Hidden error bars are smaller than symbols. 
The activation of AMT prodrugs 24 and 25 was also examined. Full consumption of prodrugs 
was observed in a similar timeframe compared to the MTX prodrugs (Figure 2, right). AMT 
prodrugs did not release AMT nor 28 within the first two hours of incubation, but instead afforded 
the corresponding phenol intermediates 26 and 27 (Scheme 4). After 2 h of assay initiation, full 
disappearance of the prodrugs was observed and 26 and 27 started to slowly release AMT and 28, 
in a H2O2 concentration independent manner as studied in a separate assay (see Figure S5). Full 
formation of products was not observed even after 48 h of incubation. The formation of the 
relatively stable intermediates 26 and 27 could potentially allow them to disperse from the 
inflammatory environment and exert non-selective drug actions upon AMT release, unlike for the 
MTX-prodrugs 11‒13 and 17, where phenol intermediates were not observed due to the faster self-
immolation. This will have to be further evaluated in a future study of the AMT prodrugs.  
Scheme 4. Activation of AMT prodrugs 24 and 25 with H2O2 to form the intermediates 26 and 27, 
respectively, which slowly release 28 and AMT. 
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Kinetic solubility. The low solubility of 11‒13 and 24 in the H2O2 activation assay required the 
use of high concentrations of DMSO (30%) in PBS. Therefore, the evaluation of the prodrug 
solubility was prioritized in the development program. Kinetic solubility in PBS was measured at 
37 oC and the results were compared to those determined for the parent drugs, showing low 
solubility (<10 µg/mL) for the methyl ester prodrugs 11‒13 and 24, according to the guidelines 
for oral administration in humans and animal dosing formulations (Table 1). On the other hand, 
prodrugs 17 and 25 showed moderate to good solubility for predicted oral dosing in humans (55 
and 48 µg/mL, respectively), although still low for animal dosing applications. The low solubility 
of 11‒13 and 24 prompted the decision to select 17 and 25 for further in vitro studies.  
Table 1. Kinetic solubility of 11, 12, 13, 17, 24, and 25. 
Prodrug 
Kinetic solubility 
µM µg/mL 
11 3.0 ± 0.5 2.0 ± 0.3 
12 3.1 ± 1.4 2.1 ± 0.9 
13 4.6 ± 0.9 3.1 ± 0.6 
17 87 ± 2.3 55 ± 1.5 
24 4.1 ± 0.2 2.5 ± 0.1 
25 83 ± 0.6 48 ± 0.4 
MTX 2137 ± 0.0 970 ± 0.0  
AMT >1000 ± 0.0 >440 ± 0.0  
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Chemical (pH 7.4), SGF, SIF, plasma, and metabolic stability. The stability of 17 and 25 was 
evaluated in different relevant physiological environments including chemical stability at blood 
pH 7.4 as well as in simulated gastric fluid (SGF), simulated intestinal fluid (SIF), human and 
mouse plasma and liver microsomes. Firstly, the half-lives t1/2 of 17 and 25 in PBS (pH 7.4) at 37 
oC were determined to 238 and 577 h, respectively, with stabilities higher than 90% after 24 h in 
both cases (Table 2 and Figure S6). Secondly, the stability in SGF and SIF was studied and half-
lives calculated to 8 and 770 h in SGF, and 239 and 866 h in SIF for 17 and 25, respectively (Table 
2 and Figure S7). The shorter half-life of 17 in SGF was found to be pH-dependent rather than a 
result of enzymatic hydrolysis (Figure S7). Thirdly, the stability in human and mouse plasma 
proved to be high, with 70% and 82% of 17 and 25 remaining after 24 h in human plasma, 
respectively, and 62% and 91% after 8 h in mouse plasma (see Figure S8). Their half-lives were 
calculated using first order kinetics and the results are shown in Table 2. Lastly, the metabolic 
stability was evaluated by the determination of intrinsic clearance (CLint) in human and mouse 
pooled liver microsomes. Intrinsic clearance of 17 and 25 was calculated to 22 and 1.2 µL/min/mg 
respectively in human microsomes, while 6.4 and 2.6 µL/min/mg in mouse microsomes (Table 2 
and Figure S9), indicating their high metabolic stability. 
Table 2. Chemical (pH 7.4), SGF, SIF, plasma, and metabolic stabilities of prodrug candidates 
17 and 25.  
 Chemical 
Stability  
(pH 7.4) 
SGF 
Stability 
SIF 
Stability 
Human 
Plasma 
Stability 
Mouse 
Plasma 
Stability 
Human 
Microsomal 
Stability 
Mouse 
Microsomal 
Stability 
Prodrug t1/2 (h) t1/2 (h) t1/2 (h) t1/2 (h) t1/2 (h) CLint (µL/min/mg) 
CLint 
(µL/min/mg) 
17 238 8 239 70 17 2.2 6.4 
25 577 770 866 56 63 1.2 2.6 
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Anti-arthritic efficacy and preliminary toxicity. The efficacy of the prodrug candidates 17 
and 25 was evaluated in the collagen type-II induced arthritis (CIA) mouse model.  This model 
has been found to be characterised by oxidative stress58 and increased concentrations of H2O2 in 
the joint tissue, paws and limbs,59,60 hence it represents a good model for the evaluation of the 
prodrug concept.  Prior to the in vivo analysis, the prodrug concept was evaluated in vitro for 17 
and 25. To this end, the cell viability inhibition of the prodrugs against two MTX- and AMT-
sensitive cancer cell lines, NCI-H460 (lung cancer) and MCF-7 (breast cancer),61 was tested. The 
prodrugs showed significantly reduced efficacy in the two cell lines when applied directly to the 
cells as compared to when they were activated by pre-incubation with non-cytotoxic concentration 
of H2O2 (Figures S10–S12). Additionally, the IC50 values of the pre-activated prodrugs 17 and 25 
showed comparable biological activity to MTX and AMT (Figure S13 and S14) in the two selected 
cancer cell lines. A detailed description of the assays can be found in the SI.  
The in vivo anti-arthritic efficacy and preliminary toxicity study was performed using a 
therapeutic intervention set up in the CIA model and the parent drugs MTX and AMT were 
included as treatment controls. Vehicle control (2% DMSO in PBS), MTX (7.0 mg/kg), and 
equimolar doses of AMT, 17, and 25 were i.p. administered on a daily basis for two weeks, starting 
at onset of disease (day 27 after first immunization). Mean arthritis severity score and average 
animal body weight were measured three times per week. Reduced incidence of arthritis and 
reduction of macroscopic arthritis score was observed both for the drugs and prodrugs in 
comparison to the control group (vehicle) (Figure 3, left). Additionally, remission of arthritis 
started to be detected at the end of the study for MTX, 17, and 25, with no statistically significant 
difference in efficacy between them. Interestingly, the AMT-group had to be sacrificed at day 33 
due to significant toxicity measured as decreased average body weight in the group, while the 
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AMT prodrug 25 did not show any sign of side-effects (Figure 3, right). Progressive weight loss 
was observed in the MTX-group towards the end of the study but not in the group treated with 17. 
These results indicate the great potential of 17 and 25 as prodrugs of MTX and AMT, respectively, 
showing comparable efficacy in managing arthritis development and control of disease activity, 
and reducing side-effects compared to the parent drugs.  
 
Figure 3. Suppression of CIA development in DBA/1J mice (left) after treatment with MTX (7 
mg/kg) and equimolar amounts of AMT (6.8 mg/kg), 17 (9.7 mg/kg), and 25 (8.8 mg/kg) (n = 8 
per group). Mice were given the indicated dose of test compound once per day, starting on day 27, 
and arthritis scoring was performed three times per week. Data represents mean values of arthritic 
score ± SEM. Statistics were calculated using a one-tailed non parametric Mann-Whitney. * p < 
0.05 and ** p  < 0.01 between MTX and vehicle and † p < 0.05 between 17 and vehicle. General 
health of mice (right) evaluated three times per week as the average body weight in groups of 
animals (n = 8) tested with vehicle, MTX, AMT, 17, and 25. Data represents mean values of 
bodyweight ± SEM. * p < 0.05 between AMT and vehicle. One animal in the vehicle and the 25 
groups were sacrificed pre-termination due to high arthritis scores. The AMT group was removed 
at day 33 due to decline in health. AMT, aminopterin; CIA, collagen induced-arthritis; CII, 
collagen type-II; MTX, methotrexate. 
Although no toxicity associated to prodrugs 17 and 25 has been observed in the animal assays 
performed, it is of relevance for future studies of the potential toxicities to also account for the 
release of quinone methides as prodrug activation end-product. Their reactivity and toxicity has 
been linked and reviewed elsewhere,62 and prior studies have demonstrated that it is possible to 
modulate these factors through judicious choice of the substitution pattern on the quinone methides 
released. Noteworthy, quinone moieties are known in long-term use marketed drugs,62 and newly 
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developed ROS-sensitive drug delivery systems which employ phenyl boronates as the responsive 
chemical entity have shown good safety profiles after long-term administration in mice.63 
CONCLUSION 
In this report, we have described the synthesis of new arylboronic acid-based hydrogen peroxide-
sensitive prodrugs of MTX and AMT for site-selective delivery of drugs to inflammatory tissues 
associated to RA with the aim of reducing side effects in MTX and AMT RA therapy. Among the 
set of prodrugs synthesized, 17 and 25 showed moderate to good solubility, high chemical stability, 
high stability in simulated gastrointestinal fluids, and high plasma and metabolic stabilities both 
in human and mouse plasma and liver microsomes. Their comparable efficacy and lower toxicity 
in comparison to parental drugs was identified using a CIA mouse model of RA. Future work will 
focus on additional in vivo studies to establish optimal dosing and to map toxicity in more detail 
to hopefully advance these promising prodrugs into clinical evaluations. 
EXPERIMENTAL SECTION 
General considerations 
Unless otherwise stated, commercially available reagents were used without further purification 
and all solvents were of HPLC quality. Reactions under nitrogen atmosphere were performed in 
oven- or flame-dried glassware and anhydrous solvents. Anhydrous CH2Cl2, CH3CN, THF, DMF, 
and toluene were obtained from Innovative Technology PS-MD-7 Pure solve solvent purification 
system. All reactions were monitored by thin-layer chromatography (TLC) and/or reversed-phased 
ultra-performance liquid chromatography mass spectrometry  
(RP-UPLC-MS). Analytical TLC was conducted on Merck aluminium sheets covered with silica 
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(C60). The plates were either visualized under UV-light or stained by dipping in a developing 
agent followed by heating. KMnO4 (3 g in water (300 mL) along with K2CO3 (20 g) and 5% 
aqueous NaOH (5 mL)) or Ninhydrin (3 g in a mixture of n-butanol (200 mL) and AcOH (6 mL)) 
were used as developing agents. Flash column chromatography was performed using Matrex 60 
Å, 35‒70 µ silica gel. All new compounds were characterized by IR, 1H NMR, 13C NMR, HRMS 
(ESI) and melting point (m.p.) when applicable. For recording of 1H NMR and 13C NMR a Bruker 
Ascend with a Prodigy cryoprobe (operating at 400 MHz for proton and 101 MHz for carbon) was 
used. Unless otherwise stated, all NMR spectra were recorded at 25 oC. The chemical shifts (δ) are 
reported in parts per million (ppm) and the coupling constants (J) in Hz. For spectra recorded in 
CDCl3, signal positions were measured relative to the signal for CHCl3 (7.26 ppm for 1H NMR 
and 77.16 ppm for 13C NMR). For spectra recorded in DMSO-d6 signal positions were measured 
relative to the signal for DMSO (δ 2.50 ppm for 1H NMR and 39.52 ppm for 13C NMR). For 
spectra recorded in D2O signal positions were measured relative to the signal for H2O (δ 4.79 ppm 
for 1H NMR at 25 oC).64 The 13C NMR signal of the ipso carbon to the boron atom was not observed 
in any characterized compound, aulthough they were identified by the characteristic HMBC 
correlation signals. Infrared (IR) spectra were recorded on a Bruker Alpha-P FT-IR (Bruker) 
instrument. Neat application into the apparatus was used for all compounds. Transmittance units 
were plotted in the y axis and wavenumber (cm-1) on the x axis. Optical rotations were measured 
on a Perkin Elmer Model 241 Polarimeter (cuvette 1.0 mL, 100 mm) using a sodium source lamp 
(589 nm, 20 oC). Melting points (m.p.) were recorded using a Stuart melting point SMP30, and 
reported in oC, uncorrected. Analytical RP-UPLC-MS (ESI) analysis was performed on a Waters 
AQUITY RP-UPLC system equipped with a diode array detector using a Thermo accucore C18 
column (d 2.6 µm, 2.1 x 50 mm; column temp: 50 °C; flow: 0.6 mL/min). Four different methods 
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were use. Method A: eluents A (0.1% HCO2H in milli-Q water) and B (0.1% HCO2H in CH3CN) 
were used in a linear gradient (5% B to 100% B) in a total run time of 2.6 min. Method B: eluents 
A (0.1% HCO2H in H2O) and B (0.1% HCO2H in CH3CN) were used in a linear gradient (5% B 
to 100% B) in a total run time of 5.0 min. Method C: eluents A (10 mM NH4OAc in milli-Q water) 
and B (0.1% NH4OAc in milli-Q water/MeCN, 90/10, v/v) were used in a linear gradient (5% B 
to 100% B) in a total run time of 2.6 min. Method D: eluents A (0.1% NH4OAc in H2O) and B 
(0.1% NH4OAc in CH3CN) were used in a linear gradient (5% B to 100% B) in a total run time of 
5.0 min. The LC system was coupled to a SQD mass spectrometer operating in both positive and 
negative electrospray modes. The temperature for all recordings was 20 °C. Analytical LC-HRMS 
(ESI) analysis was performed on an Agilent 1100 RP-LC system equipped with a diode array 
detector using a Phenomenex Luna C18 column (d 3 µm, 2.1 x 50 mm; column temp: 40 °C; flow: 
0.4 mL/min). Eluents A (0.1% HCO2H in H2O) and B (0.1% HCO2H in CH3CN) were used in a 
linear gradient (20% B to 100% B) in a total run time of 15 min. The LC system was coupled to a 
Micromass LCT orthogonal time-of-flight mass spectrometer equipped with a Lock Mass probe 
operating in positive or negative electrospray mode. Purification of reactions by preparative RP-
HPLC was performed on a Waters Alliance reverse-phase HPLC system consisting of a Waters 
2545 Binary Gradient Module equipped with either an xBridge BEH C18 OBD Prep Column (130 
Å, 5 µm, 30 x 150 mm) or an xBridge Peptide BEH C18 OBD Prep Column (130 Å, 5 µm, 19 mm 
x 100 mm) both operating at 20 °C and a flow rate of 20 mL/min, a Waters Photodiode Array 
Detector (detecting at 210‒600 nm), a Waters UV Fraction Manager, and a Waters 2767 Sample 
Manager. Elution was carried out in a reversed-phase gradient fashion combining A1 (0.1% 
HCO2H in milli-Q water) and B1 (0.1% HCO2H in CH3CN) or A2 (5 mM NH4OAc in H2O) and 
B2 (5 mM NH4OAc in CH3CN): 5% B to 70 % B in 10 min, hold for 3.5 min, then 70% B to 100% 
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B in 1.5 min, and hold 3 minutes. Total run time: 20 min. The purity of the compounds was 
assessed by RP-UPLC-UV and NMR, and purities ≥95% were considered acceptable for 
evaluation purposes both in vitro and in vivo assays.  
Synthesis  
3-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonochloridate (4b). 
General procedure A: a suspension of 3b (0.9 g, 5.4 mmol) and pinacol (0.7 g, 6.0 mmol) in 
anhydrous THF (25 mL) was refluxed for 16 h under an N2 atmosphere. The solids dissolved 
during the reaction time. Then, the mixture was concentrated in vacuo and the residue purified by 
flash column chromatography on silica gel using a mixture of CH2Cl2/EtOAc (9/1, v/v) as the 
eluent to give the title compound 4b as a clear oil (1.27 g, 95%) which solidified upon storage in 
the refrigerator. Rf = 0.84 (silica, CH2Cl2/EtOAc, 1/1, v/v); m.p.: 38.5 – 41.3 oC; IR (neat, cm-1): 
3390.6, 2978.1, 2925.3, 2867.7, 1609.0, 1347.1, 335.9; 1H NMR (400 MHz, CDCl3) δ 7.76 (d,  
J = 7.4 Hz, 1H), 7.17 – 7.09 (m, 2H), 4.67 (s, 2H), 2.54 (s, 3H), 1.34 (s, 12H); 13C NMR (101 
MHz, CDCl3) δ 145.5, 143.6, 136.4, 128.3, 123.2, 83.6, 65.4, 25.0, 22.3; HRMS (ESI) m/z: calcd 
for C14H22BO3 [M+Na]+ 271.1476, found 271.1512. 
(3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol (4c). Following 
general procedure A using 3c (0.90 g, 5.30 mmol), the title compound 4c was afforded as a clear 
oil (1.26 g, 94%) after purification by flash column chromatography on silica gel using a mixture 
of CH2Cl2/EtOAc (9/1, v/v) as the eluent. The oil became a white solid upon storage in the 
refrigerator. Rf = 0.71 (silica, eluent CH2Cl2/EtOAc, 1/1, v/v); m.p.: 52.5 – 56.4 oC (Litt.65 35‒38); 
IR (neat, cm-1): 3424.6, 2978.6, 2932.3, 2864.3, 1624.1, 1351.8; 1H NMR (400 MHz, CDCl3) δ 
7.77 – 7.67 (m, 1H),  7.12 (d, J = 7.6 Hz, 1H), 7.06 (d, J = 10.1 Hz, 1H), 4.72 (s, 2H), 1.36 (s, 
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12H);65 13C NMR (101 MHz, CDCl3) δ 167.6 (d, J = 251.4 Hz), 147.2 (d, J = 8.0 Hz), 137.2 (d, J 
= 8.4 Hz), 121.7 (d, J = 2.9 Hz), 113.4 (d, J = 24.7 Hz), 84.0, 64.6, 25.0.65  
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonochloridate (5a). General 
procedure B: a solution of 4a (2.0 g, 8.54 mmol) in anhydrous dioxane (25 mL) was treated with 
phosgene (20% in toluene, 22.6 mL, 42.7 mmol) and the reaction was stirred for 20 h under an N2 
atmosphere at 21 oC. The mixture was concentrated in vacuo, redissolved and concentrated with 
toluene (2x) to afford the crude title compound 5a as a clear oil (2.5 g, > 95%). The crude 
chloroformate was used in subsequent reactions within few hours after its isolation. 1H NMR (400 
MHz, CDCl3) δ 7.84 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 5.31 (s, 2H), 1.35 (s, 12H);66 
13C NMR (101 MHz, CDCl3) δ 150.8, 136.2, 135.4, 128.0, 84.2, 73.4, 25.0.66  
3-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonochloridate (5b). 
Following general procedure B using 4b (1.2 g, 4.8 mmol), the title compound 5b was afforded 
as a clear oil (1.5 g, >95%). The crude chloroformate was used in subsequent reactions within few 
hours after its isolation. 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.0 Hz, 1H), 7.20 – 7.13 (m, 
2H), 5.26 (s, 2H), 2.55 (s, 3H), 1.34 (s, 12H); 13C NMR (101 MHz, CDCl3) δ 150.8, 145.7, 136.5, 
135.7, 130.1, 125.0, 83.8, 73.5, 25.0, 22.3. 
3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl carbonochloridate (5c). 
Following general procedure B using 4c (1.2 g, 4.8 mmol), the crude product 5c was afforded as 
a white solid (1.5 g, >95%). The crude chloroformate was used in subsequent reactions within few 
hours after isolation. 1H NMR (400 MHz, CDCl3) δ 7.77 (dd, J = 7.5, 6.1 Hz, 1H), 7.15 (dd, J = 
7.5, 1.3 Hz, 1H), 7.07 (dd, J = 9.6, 1.1 Hz, 1H), 5.29 (s, 2H), 1.36 (s, 12H);65 13C NMR (101 MHz, 
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CDCl3) δ 167.7 (d, J = 251 Hz), 150.8, 138.92 (d, J = 8.3 Hz), 137.6 (d, J = 8.5 Hz), 123.5 (d, J = 
3.2 Hz), 115.3 (d, J = 25.4 Hz), 84.3 (s), 72.2 (s), 25.0 (s).65 
4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzoic acid (7). 2,4-Diamino-6-
(hydroxymethyl)pteridine hydrochloride 6·HCl (4.4 g, 19 mmol) was dissolved in hot water (150 
mL) and after cooling to 21 oC the solution was neutralized with 1 M aq. NaOH to pH ~ 7 (ca. 20 
mL). The formed precipitates were collected by filtration, washed with water, and dried in vacuo 
over P2O5 to afford an orange-beige solid corresponding to 2,4-diamino-6-
(hydroxymethyl)pteridine. The solid was suspended in anhydrous DMA (25 mL) and 
triphenylphosphine dibromide (18 g, 43 mmol) was added to the suspension. The turbid and dark 
mixture was stirred for 24 h under an N2 atmosphere at 20 oC. Then, 4-aminobenzoic acid (3.0 g, 
20 mmol) was added to the reaction and stirred for an additional three days. The reaction mixture 
was poured into 250 mL of 0.33N NaOH and the precipitate was filtered off. The filtrate was 
neutralized with 10% aq. acetic acid (ca. 20 mL) and the precipitate formed upon neutralization 
was filtered off, washed with water, triturated over MeOH, filtered, and dried in vacuo to afford 
the title compound 7 as an orange-beige solid (5.70 g, 91%). m.p.: > 240 oC (decomp.) (lit.52  
242 oC); IR (neat, cm-1): 3378.7, 3279.5, 2233.3, 1663.6, 1598.6, 1288.4, 1186.0;67 1H NMR (400 
MHz, DMSO-d6) δ 12.15 (br s, 1H), 8.63 (s, 1H),  8.17 (br s, 1H), 7.94 (br s, 1H), 7.73 (d,  
J = 9.0 Hz, 2H), 7.04 (br s, 2H), 6.83 (d, J = 9.0 Hz, 2H), 4.81 (s, 2H), 3.23 (s, 3H);26 13C NMR 
(101 MHz, DMSO-d6) δ 167.8, 163.2, 161.1, 152.3, 149.5, 147.8, 131.5, 122.2, 118.1, 111.7, 
100.0, 55.2, 39.6. 
Dimethyl L-glutamate hydrochloride (9·HCl). Thionyl chloride (5.0 mL, 68 mmol) was added 
dropwise to 50 mL of anhydrous MeOH at 0 oC. The mixture was stirred for 30 min at the same 
temperature followed by addition of L-glutamic acid 8 (5.0 g, 34 mmol). Then, the reaction was 
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stirred under an N2 atmosphere for 3 days at 21 oC and concentrated in vacuo to afford the title 
compound 9·HCl as a colourless solid (7.19 g, >95%). The crude product was used without further 
purification in the next reactions. m.p.: 63.2 – 64.0 oC (lit.68 77‒79); [𝛼𝛼]𝐷𝐷20 = +25.0 (c 5.0, H2O)69; 
IR (neat, cm-1): 2952.45, 2902.73, 2852.33, 1728.6770; 1H NMR (400 MHz, D2O) δ 4.24 – 4.19 
(m, 1H), 3.85 (s, 3H), 3.73 (s, 3H), 2.65 (td, J = 7.3, 2.2 Hz, 2H), 2.37 – 2.13 (m, 2H);70 13C NMR 
(101 MHz, D2O) δ 174.8, 170.2, 53.6, 52.4, 52.0, 29.2, 24.7.70 
Dimethyl (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamate (10). 
To a solution of 7 (3.0 g, 9.2 mmol) in anhydrous DMF (80 mL) was added Et3N (6.4 mL, 46.1 
mmol) followed by PyBOP (6.5 g, 12.4 mmol). The mixture was stirred for 30 min under an N2 
atmosphere at 21 oC. Then, 9·HCl (2.1 g, 9.9 mmol) was added and the reaction mixture was stirred 
for 5 h at the same temperature. Then, the reaction was filtered through a path of Celite® and the 
filtrate concentrated in vacuo. Next, the residue was dissolved in a mixture of EtOAc/CHCl3 (150 
mL, 1/1) and poured into 750 mL of Et2O at 0 oC under strong stirring. The resultant suspension 
was filtered off, washed with Et2O and cold water, triturated in hot MeOH, and filtered off again. 
The resultant orange solid wash purified by flash column chromatography on silica gel using a 
mixture of CH2Cl2/MeOH (92.5/7.5, v/v) as the eluent to give the title compound 10 as a yellow 
solid (2.39 g, 54%). Rf = 0.48 (silica, MeOH/CH2Cl2, 1/9, v/v); m.p.: >168.6 (decomp.) (lit.52 130‒
134); [α]𝐷𝐷20 = +2.6 (c 0.5, DMSO); IR (neat, cm-1): 3306.96, 3128.91, 2950.99, 2923.52, 1731.36, 
1626.09, 1604.36, 1503.14, 1435.41; 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.34 (d, J = 
7.4 Hz, 1H), 7.77 – 7.69 (m, 3H), 7.45 (br s, 1H), 6.82 (d, J = 8.8 Hz, 2H), 6.61 (br s, 2H), 4.78 (s, 
2H), 4.39 (ddd, J = 9.4, 7.4, 5.6 Hz, 1H), 3.61 (s, 3H), 3.57 (s, 3H), 3.21 (s, 3H), 2.41 (t, J = 7.4 
Hz, 2H), 2.17 –1.72 (m, 2H);71 13C NMR (101 MHz, DMSO-d6) δ 172.7, 172.6, 166.4, 162.9, 
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162.7, 155.2, 151.0, 149.2, 145.9, 129.0, 121.4, 120.7, 111.0, 54.9, 51.8, 51.7, 51.4, 38.7, 30.0, 
25.8;71 HRMS (ESI) m/z: calcd for C22H27N8O5 [M+H]+ 483.2099, found 483.2119.  
(S)-(4-((((2-Amino-6-(((4-((1,5-dimethoxy-1,5-dioxopentan-2-
yl)carbamoyl)phenyl)(methyl)amino)methyl)pteridin-4-yl)carbamoyl)oxy)methyl) 
phenyl)boronic acid (11). General procedure C: to a suspension of 10 (313 mg, 0.68 mmol) in 
anhydrous CH2Cl2 (25 mL) was added DMAP (417 mg, 3.42 mmol) followed by DIPEA (0.60 
mL, 3.42 mmol). The mixture was cooled to 0 oC and a solution of 5a (1.01 g, 3.42 mmol) in 
CH2Cl2 (10 mL) was added dropwise. The reaction was allowed to warm to 21 oC and stirred for 
6 h under an N2 atmosphere. Then, the mixture was diluted with CH2Cl2 (100 mL), washed with 
0.1 M aq. HCl (2 x 75 mL), sat. aq. NaHCO3 (2 x 75 mL), and brine (75 mL). The organic layer 
was dried over Na2SO4, filtered, and concentrated in vacuo to afford a yellow solid that was 
purified by reversed-phase preparative HPLC. The CH3CN/H2O collected fractions containing the 
pinacolate intermediate were combined into a 250 mL round bottom flask and HCl cc. (0.3 mL, 
pH ~ 2) was added. The reaction mixture was stirred for 16 h at 21 oC and quenched with sat. aq. 
NaHCO3 (ca. 50 mL). After removal of the CH3CN under rotatory evaporation the formed 
precipitate was filtered off, washed with H2O and dried in vacuo to afford the title compound 11 
as a yellow solid (122 mg, 27%). Additional preparative HPLC purification was sometimes needed 
in specific substrates. m.p.: >153.0 oC (decomp.); [𝛼𝛼]𝐷𝐷20 = +4.7 (c 0.32, DMSO); IR (neat, cm-1): 
3354.4, 3233.1, 2954.7, 1732.5, 1627.5, 1605.2, 1573.9, 1536.9, 1198.5, 1173.2; 1H NMR (400 
MHz, DMSO-d6) δ 9.88 (br s, 1H), 8.68 (s, 1H), 8.34 (d, J = 7.5 Hz, 1H), 8.08 (s, 2H), 7.82 (d, J 
= 7.8 Hz, 2H), 7.72 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 7.8 Hz, 2H), 7.27 (br s, 2H), 6.82  (d, J = 8.8 
Hz, 2H), 5.24 (s, 2H), 4.84 (s, 2H), 4.39 (ddd, J = 9.3, 7.5, 5.7 Hz, 1H), 3.60 (s, 3H), 3.56 (s, 3H), 
3.20 (s, 3H), 2.40 (t, J = 7.4 Hz, 2H), 2.15 – 1.90 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 
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172.7, 172.6, 166.4, 162.0, 157.8, 155.1, 151.1, 150.7, 150.3, 148.0, 137.7, 134.2, 129.0, 127.0, 
120.9, 120.9, 111.1, 66.7, 54.9, 51.8, 51.7, 51.4, 38.9, 30.0, 25.8. HRMS (ESI) m/z: calcd for 
C30H34BN8O9 [M+H]+ 661.2536, found 661.2566. 
 (S)-(4-((((2-Amino-6-(((4-((1,5-dimethoxy-1,5-dioxopentan-2-
yl)carbamoyl)phenyl)(methyl)amino)methyl)pteridin-4-yl)carbamoyl)oxy)methyl)-2-
methylphenyl)boronic acid (12). Following general procedure C using 5b (1.45 g, 4.66 mmol), 
the title compound 12 was afforded as a yellow solid (179 mg, 22%). m.p.: >166.0 oC 
(decomp.); [𝛼𝛼]𝐷𝐷20 = +4.0 (c 0.7, DMSO); IR (neat, cm-1): 3340.8, 3230.2, 2951.6, 1741.8, 1604.5, 
1510.3, 1197.7, 1166.6, 1028.4; 1H NMR (400 MHz, DMSO-d6) δ 9.82 (s, 1H), 8.69 (s, 1H), 8.34 
(d, J = 7.5 Hz, 1H), 8.02 (s, 2H), 7.72 (d, J = 9.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 1H), 7.28  (br s, 
2H), 7.23 – 7.16 (m, 2H), 6.83 (d, J = 9.0 Hz, 2H), 5.18 (s, 2H), 4.84 (s, 2H), 4.39 (ddd,  
J = 9.5, 7.5, 5.4 Hz, 1H), 3.61 (s, 3H), 3.56 (s, 3H), 3.20 (s, 3H), 2.44 – 2.37 (m, 5H), 2.13 – 1.88 
(m, 2H).; 13C NMR (101 MHz, DMSO-d6) δ 172.7, 172.6, 166.4, 162.0, 157.8, 155.1, 151.0, 150.7, 
150.2, 147.9, 141.4, 136.2, 133.3, 129.0, 128.9, 124.3, 120.9, 120.8, 111.1, 66.7, 54.9, 51.8, 51.7, 
51.3, 38.9, 29.9, 25.8, 22.1; HRMS (ESI) m/z: calcd for C31H36BN8O9 [M+H]+ 675.2693, found 
675.2720. 
 (S)-(4-((((2-Amino-6-(((4-((1,5-dimethoxy-1,5-dioxopentan-2 
yl)carbamoyl)phenyl)(methyl)amino)methyl)pteridin-4-yl)carbamoyl)oxy)methyl)-2-
fluorophenyl)boronic acid (13). Following general procedure C using 5c (1.30 g, 4.19 mmol), 
the title compound 13 was afforded as a yellow solid (237 mg, 34%). m.p.: >158.1 oC 
(decomp.); [𝛼𝛼]𝐷𝐷20 = +4.3 (c 0.6, DMSO); IR (neat, cm-1): 3499.4, 3448.3, 3360.5, 3326.1, 3218.7, 
2952.9, 1760.0, 1733.0, 1625.6, 1490.3, 1196.3, 1171.6; 1H NMR (400 MHz, DMSO-d6) δ 9.95 
(s, 1H), 8.69 (s, 1H), 8.34 (d, J = 7.5 Hz, 1H), 8.22 (s, 2H), 7.72 (d, J = 8.8 Hz, 2H), 7.59 (t,  
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J = 7.0 Hz, 1H), 7.40 – 7.20 (m, 4H), 6.83 (d, J = 8.9 Hz, 2H), 5.25 (s, 2H), 4.85 (s, 2H), 4.39 
(ddd, J = 9.4, 7.5, 5.7 Hz, 1H), 3.61 (s, 3H), 3.56 (s, 3H), 3.20 (s, 3H), 2.41 (t, J = 7.4 Hz, 2H), 
2.16 – 1.86 (m, 2H); 13C NMR (100 MHz, DMSO-d6) δ 173.2, 173.04, 166.9, 165.9 (d, J = 244.5 
Hz), 162.5, 158.3, 155.6, 151.5, 151.1, 150.7, 148.4, 140.6 (d, J = 8.3 Hz), 136.0(d, J = 9.8 Hz), 
129.5, 123.4 (d, J = 2.7 Hz), 121.4, 121.3, 114.5 (d, J = 25.5 Hz), 111.6, 66.2, 55.4, 52.3, 52.2, 
51.8, 39.1, 30.4, 26.2; HRMS (ESI) m/z: calcd for C30H33BFN8O9 [M+H]+ 679.2442, found 
679.2455. 
Bis(4-methoxybenzyl) (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-
glutamate (14). A solution of methotrexate (1.0 g, 2.20 mmol) in anhydrous DMF (50 mL) was 
treated with 1,1,3,3-tetramethylguanidine (0.55 mL, 4.4 mmol) at 0 oC and the mixture was stirred 
for 30 min under an N2 atmosphere. Then, 4-methoxybenzyl chloride (0.59 mL, 4.4 mmol) was 
added dropwise and the mixture was allowed to warm to 21 oC and stirred for 24 h. Next, volatiles 
were removed in vacuo and the crude was purified by flash column chromatography on silica gel 
using a mixture of CH2Cl2/MeOH (gradient elution from 97/3 to 94/6, v/v) as the eluent to give 
the title compound 154as a yellow solid (915 mg, 60%). Rf = 0.24 (silica, CH2Cl2/MeOH, 95/5, 
v/v); m.p.: 96.5 – 99.2 oC; [𝛼𝛼]𝐷𝐷20 = +8.0 (c 1.0, DMSO); IR (neat, cm-1): 3325.0, 3181.8, 2936.0, 
2835.6, 1730.6, 1603.3, 1511.2, 1442.8;  1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.34 (d, 
J = 7.5 Hz, 1H), 7.71 (d, J = 8.9 Hz, 2H), 7.65 (br s, 1H), 7.43 (br s, 1H), 7.27 (d, J = 6.9 Hz, 2H), 
7.25 (d, J = 6.9 Hz, 2H), 6.90 – 6.86 (m, 4H), 6.82 (d, J = 8.9 Hz, 2H), 6.60 (br s, 2H), 5.10 – 4.99 
(m, 2H), 4.97 (s, 2H), 4.78 (s, 2H), 4.42 (ddd, J = 9.6, 7.5, 5.4 Hz, 1H), 3.73 (s, 6H), 3.21 (s, 3H), 
2.42 (t, J = 7.6 Hz, 2H), 2.13 – 1.90 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 172.1, 172.0, 
166.5, 162.9, 162.7, 159.1, 155.2, 151.0, 149.2, 145.9, 129.8, 129.7, 129.0, 128.0, 127.9, 121.4, 
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120.8, 113.8, 111.0, 65.7, 65.3, 55.1, 54.8, 51.9, 38.8, 30.2, 25.8; HRMS (ESI) m/z: calcd for 
C36H39N8O7 [M+H]+ 695.2936, found 695.2954. 
Bis(4-methoxybenzyl) (4-(((2-amino-4-((((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy)carbonyl)amino)pteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamate 
(15). To a suspension of 15 (800 mg, 1.15 mmol) in anhydrous CH2Cl2 (25 mL) was added DMAP 
(703 mg, 5.76 mmol) followed by DIPEA (1.0 mL, 5.76 mmol). The mixture was cooled to 0 oC 
and a solution of 5a (1.71 g, 5.76 mmol) in CH2Cl2 (10 mL) was added dropwise. The reaction 
was allowed to warm to 21 oC and stirred for 5 h under an N2 atmosphere. The mixture was then 
diluted with CH2Cl2 (100 mL), washed with 1 M aq. HCl (2 x 75 mL), sat. aq. NaHCO3 (2 x 75 
mL), and brine (75 mL). The organic layer was dried over Na2SO4, filtered and concentrated in 
vacuo. Purification of the residue by reversed-phase preparative HPLC afforded the title compound 
15 as a yellow solid (800 mg, 73%). m.p.: >105.0 (decomp.); [𝛼𝛼]𝐷𝐷20 = +8.8 (c 0.42, DMSO); IR 
(neat, cm-1): 3351.5, 3230.0, 2975.5, 2836.5, 1731.3, 1605.6, 1512.6, 1356.9; 1H NMR (400 MHz, 
DMSO-d6) 9.87 (s, 1H), 8.69 (s, 1H), 8.34 (d, J = 7.5 Hz, 1H), 7.72 (d, J = 7.9 Hz, 4H), 7.47 (d, J 
= 7.9 Hz, 2H), 7.33 – 7.17 (m, 6H), 6.91 – 6.85 (m, 4H), 6.82 (d, J = 9.0 Hz, 2H), 5.26 (s, 2H), 
5.06 – 4.98 (m, 2H), 4.96 (s, 2H), 4.84 (s, 2H), 4.43 (ddd, J = 9.5, 7.4, 5.4 Hz, 1H), 3.72 (s, 6H), 
3.19 (s, 3H), 2.41 (t, J = 7.4 Hz, 2H), 2.13 – 1.91 (m, 2H), 1.29 (s, 12H); 13C NMR (101 MHz, 
DMSO-d6) δ 172.1, 172.0, 166.5, 162.0, 159.1 (2C), 157.8, 155.1, 151.1, 150.7, 150.3, 148.0, 
139.3, 134.6, 129.8, 129.7, 129.0, 128.0, 127.9, 127.3, 121.0, 120.8, 113.8 (2C), 111.1, 83.7, 66.5, 
65.7, 65.3, 55.1 (2C), 54.9, 51.9, 39.5, 30.2, 25.8, 24.7; HRMS (ESI) m/z: calcd for C50H56BN8O11 
[M+H]+ 955.4156, found 955.4191. 
 (S)-(4-((((2-Amino-6-(((4-((1,5-bis((4-methoxybenzyl)oxy)-1,5-dioxopentan-2-
yl)carbamoyl)phenyl)(methyl)amino)methyl)pteridin-4-
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yl)carbamoyl)oxy)methyl)phenyl)boronic acid (16). To a solution of 15 (0.70 g, 0.73 mmol) in 
a mixture of CH3CN/THF/H2O (200 mL, 2/1/1, v/v) was added cc. HCl until pH ~ 2. The reaction 
mixture was stirred at 21 oC for 6 h followed by neutralization with sat. aq. NaHCO3 (approx. 50 
mL). After removal of organic solvents in vacuo, the formed precipitate was filtered off, washed 
with H2O, and purified by reversed-phase preparative HPLC to afford the title compound 16 as a 
yellow solid (199 mg, 31%). m.p.: >147.8 oC; [𝛼𝛼]𝐷𝐷20 = +8.3 (c 0.99, DMSO); IR (neat, cm-1): 
3362.3, 3230.6, 2954.1, 2836.7, 1732.0, 1628.9, 1605.5, 1512.4, 1198.7, 1170.9; 1H NMR (400 
MHz, DMSO-d6) δ 9.10 (br s, 1H), 8.64 (br s, 1H), 8.49 (s, 2H), 8.35 (d, J = 7.5 Hz, 1H), 7.78 (d, 
J = 7.9 Hz, 2H), 7.71 (d, J = 8.9 Hz, 2H), 7.40 (d, J = 7.9 Hz, 2H), 7.37 – 7.10 (m, 6H), 6.87 (d, J 
= 8.7 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 9.0 Hz, 1H), 5.21 (s, 2H), 5.10 – 4.98 (m, 2H), 
4.96 (s, 2H), 4.83 (s, 2H), 4.42 (ddd, J = 9.6, 7.4, 5.4 Hz, 1H), 3.72 (s, 6H), 3.19 (s, 3H), 2.41 (t, J 
= 7.6 Hz, 2H), 2.15 – 1.79 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 172.2, 172.0, 166.6, 162.1, 
159.1 (2C), 157.8, 155.2, 151.1, 150.7, 150.3, 148.0, 132.7, 134.3, 129.9, 129.7, 129.1, 128.0, 
127.9, 127.1, 121.0, 120.9, 113.8 (2C), 111.1, 66.7, 65.8, 65.4, 55.1 (2C), 54.9, 51.9, 39.35, 30.2, 
25.8; HRMS (ESI) m/z: calcd for C44H46BN8O11 [M+H]+ 873.3374, found 873.3405.  
(4-(((2-amino-4-((((4-Boronobenzyl)oxy)carbonyl)amino)pteridin-6-
yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid (17). A solution of 16 (150 mg, 0.17mmol) 
in a mixture of 5% TFA in anhydrous CH2Cl2 (16 mL) was stirred for 25 min under an N2 
atmosphere at 21 oC. The crude mixture was then concentrated in vacuo and the residue purified 
by reversed-phase preparative HPLC to afford the title compound 17 as an yellow/orange solid (59 
mg, 54%). m.p.: >200 oC (decomp.); [𝛼𝛼]𝐷𝐷20 = +10.0 (c 0.50, DMSO); IR (neat, cm-1): 3336.8, 
3203.3, 2929.5, 1728.8, 1604.5, 1505.5, 1199.4, 1171.1; 1H NMR (400 MHz, DMSO-d6) δ 12.29 
(br s, 2H), 9.89 (s, 1H), 8.68 (s, 1H), 8.20 (d, J = 7.8 Hz, 1H), 8.07 (s, 2H), 7.82 (d, J = 7.9 Hz, 
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2H), 7.73 (d, J = 8.9 Hz, 2H), 7.43 (d, J = 7.9 Hz, 2H), 7.28 (br s, 2H), 6.82 (d, J = 8.9 Hz, 2H), 
5.24 (s, 2H), 4.84 (s, 2H), 4.34 (ddd, J = 9.7, 7.8, 5.0 Hz, 1H), 3.19 (s, 3H), 2.31 (t, J = 7.5 Hz, 
2H), 2.11 – 1.99 (m, 1H), 1.99 – 1.79 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ 173.9, 173.7, 
166.3, 162.0, 157.8, 155.1, 151.0, 150.7, 150.3, 148.0, 137.7, 134.2, 129.0, 127.0, 121.3, 120.9, 
111.1, 66.7, 54.9, 51.7, 39.0, 30.4, 26.0; HRMS (ESI) m/z: calcd for C28H28BN8O9 [M-H]- 
631.2078, found 631.2028. 
4-(((Benzyloxy)carbonyl)amino)benzoic acid (19). To a solution of 4-methylaminobenzoic 
acid 18 (4.11 g, 29.9 mmol) and NaHCO3 (22.6 g, 269 mmol) in a mixture of H2O/THF (100 mL, 
1/1, v/v) was added benzyl chloroformate (4.26 mL, 29.9 mmol) dropwise at 0 oC. The reaction 
mixture was stirred for 4 h at 21 oC followed by addition of 20 mL of water. Then, the mixture 
was stirred for an additional 16 h followed by acidification with 1 M aq. HCl to pH ~ 3. Next, the 
precipitate was filtered off and dried in vacuo to afford 19 as a white solid (7.2 g, 89%). m.p.: 
213.0–217.0 oC (lit.72 217 oC, decomp.); IR (neat, cm-1): 3324.4, 2951.7, 2677.4, 2557.2, 1702.1, 
1672.4, 1528.6, 1512.8, 1225.8, 1062.6; 1H NMR (400 MHz, DMSO-d6) δ 12.66 (br s, 1H), 10.15 
(s, 1H), 7.87 (d, J = 8.7 Hz, 2H), 7.58 (d, J = 8.7 Hz, 2H), 7.51 – 7.17 (m, 5H), 5.17 (s, 2H);73 13C 
NMR (101 MHz, DMSO-d6) δ 167.0, 153.2, 143.3, 136.3, 130.5, 128.5, 128.2, 128.2, 124.5, 117.3, 
66.1.74 
Dimethyl (4-(((benzyloxy)carbonyl)amino)benzoyl)-L-glutamate (20). To a suspension of 19 
(2.90 g, 10.7 mmol) in anhydrous CH2Cl2 was added 1 drop of DMF followed by thionyl chloride 
(3.88 mL, 53.4 mmol) and the reaction mixture was refluxed for 24 h under an N2 atmosphere. 
Next, all volatiles were removed in vacuo to afford the acyl chloride as a pale yellow solid (3.1 g, 
>95%) which was added to a stirred mixture of 9·HCl (2.40 g, 11.3 mmol) and Et3N in anhydrous 
CH2Cl2 (100 mL) and an additional 2 h stirring was applied under an N2 atmosphere at 21 oC. The 
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mixture was then diluted with EtOAc (250 mL), washed with 1 M aq. HCl (2 x 150 mL), sat. aq. 
NaHCO3 (2 x 150 mL), and brine (200 mL), dried over Na2SO4, filtered, and concentrated in vacuo 
to afford the title compound 20 as a white solid (4.3 g, 97%). m.p.: 121.7–124.0 oC; [𝛼𝛼]𝐷𝐷20 = -16.2 
(c 1.0, MeOH); IR (neat, cm-1): 3378.3, 3297.8, 2952.4, 1730.5, 1627.7, 1526.8, 1227.4; 1H NMR 
(400 MHz, DMSO-d6) δ 10.07 (s, 1H), 8.60 (d, J = 7.4 Hz, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.55 (d, 
J = 8.8 Hz, 2H), 7.50 – 7.26 (m, 5H), 5.18 (s, 2H), 4.44 (ddd, J = 9.5, 7.4, 5.4 Hz, 1H), 3.64 (s, 
3H), 3.59 (s, 3H), 2.45 (t, J = 7.5 Hz, 2H), 2.22 – 1.83 (m, 2H); 13C NMR (101 MHz, DMSO-d6) 
δ 172.7, 172.4, 166.1, 153.2, 142.1, 136.4, 128.5 (2C), 128.2, 128.1, 127.3, 117.2, 66.0, 51.9, 51.9, 
51.4, 29.9, 25.7; HRMS (ESI) m/z: calcd for C22H25N2O7 [M+H]+ 429.1656, found 429.1676. 
Dimethyl (4-aminobenzoyl)-L-glutamate hydrochloride (21·HCl). A solution of 20 (2.0 g, 4.8 
mmol) in anhydrous MeOH (100 mL) was treated with Pd/C (200 mg, 10% w/w). The mixture 
was stirred for 12 h under a H2 atmosphere at 21 oC, then filtered through a path of Celite®, 
concentrated in vacuo over silica gel and purified by flash column chromatography on silica gel 
using a mixture of EtOAc/Hep (2/1, v/v) as the eluent to give a clear oil corresponding to the free 
amine 21. Treatment with 2 M HCl in ether afforded the hydrochloride salt 21·HCl as a white solid 
(1.3 g, 95%). Rf = 0.38 (free amine; EtOAc/Hep, 4/1, v/v); m.p.: 65.2 – 70.0 oC; [𝛼𝛼]𝐷𝐷20 = -17.8 (c 
1.26, H2O); IR (neat, cm-1): 3270.9, 2952.3, 2834.2, 2577.2, 1731.4, 1641.3, 1609.8, 1538.9, 
1501.4, 1436.4, 1206.7, 1171.7; 1H NMR (400 MHz, D2O) δ 7.78 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 
8.5 Hz, 2H), 4.58 (dd, J = 9.4, 5.2 Hz, 1H), 3.70 (s, 3H), 3.56 (s, 3H), 2.49 (t,  
J = 7.0 Hz, 2H), 2.35 – 2.20 (m, 1H), 2.10 (ddt, J = 14.2, 9.4, 6.9 Hz, 1H); 13C NMR (101 MHz, 
D2O) δ 175.8, 173.7, 169.8, 136.8, 131.5, 129.2, 121.9, 53.0, 52.7, 52.3, 30.2, 25.5; HRMS (ESI) 
m/z: calcd for C14H19N2O5 [M+H]+ 295.1288, found 295.1297. 
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 (S)-(4-(((4-((1,5-Dimethoxy-1,5-dioxopentan-2-
yl)carbamoyl)phenyl)amino)methyl)phenyl) boronic acid (22). To a solution of 21⋅HCl (0.80 
g, 2.42 mmol) in anhydrous MeOH was added (4-formylphenyl)boronic acid (0.55 g, 3.67 mmol) 
followed by portion-wise addition of NaBH3CN (0.80 g, 12.1 mmol). The reaction mixture was 
stirred for 12 h under an N2 atmosphere at 21 oC. Extra (4-formylphenyl)boronic acid (0.55 g, 3.67 
mmol) was then added to the stirred mixture followed by an additional 24 h of stirring for 
completion of the reaction. Next, the crude mixture was concentrated in vacuo, redissolved in 
EtOAc (150mL), and washed with sat. aq. NaHCO3 (2 x 150 mL) and brine (150 mL). The organic 
phase was dried over Na2SO4, filtered, and concentrated in vacuo to afford a pale yellow solid. 
Purification by reversed-phase preparative HPLC afforded the title compound 22 as a white solid 
(699 mg, 67%). Rf = 0.77 (silica, MeOH/CH2Cl2, 1/1, v/v); m.p.: 84.1‒88.2 oC; [𝛼𝛼]𝐷𝐷20 = -16.3 (c 1.04, DMSO); IR (neat, cm-1): 3382.1, 2951.9, 1726.9, 1601.9, 1506.4, 1330.4; 
1H NMR (400 MHz, DMSO-d6) δ 8.24 (d, J = 7.5 Hz, 1H), 7.98 (s, 2H), 7.73 (d, J = 7.8 Hz, 2H), 
7.62 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 7.8 Hz, 2H), 6.84 (t, J = 6.0 Hz, 1H), 6.58 (d, J = 8.6 Hz, 2H), 
4.38 (ddd, J = 9.5, 7.5, 5.6 Hz, 1H), 4.33 (d, J = 6.0 Hz, 2H), 3.61 (s, 3H), 3.57 (s, 3H), 2.41 (t, J 
= 7.4 Hz, 2H), 2.14 – 2.03 (m, 1H), 2.02 – 1.86 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ 172.8, 
172.7, 166.6, 151.4, 141.6, 134.2, 129.0, 126.2, 120.4, 111.1, 51.8, 51.7, 51.4, 46.0, 30.0, 25.8; 
HRMS (ESI) m/z: calcd for C21H26BN2O7 [M+H]+ 429.1828, found 429.1850.  
(S)-(4-((((2,4-Diaminopteridin-6-yl)methyl)(4-((1,5-dimethoxy-1,5-dioxopentan-2-
yl)carbamoyl)phenyl)amino)methyl)phenyl)boronic acid (24). A solution of 22 (461 mg, 1.08 
mmol) and 6-(bromomethyl)pteridine-2,4-diamine hydrobromide 23·HBr (515 mg, 1.38 mmol) in 
anhydrous DMA (4.85 mL) was stirred for three days under an N2 atmosphere at 55 oC. Then, 
Et3N (79 µL, 3.21 mmol) was added to the mixture followed by addition of H2O (approx. 30 mL). 
  
 30 
The orange precipitate was filtered off and purified by reversed-phase preparative HPLC to afford 
24 as a yellow solid (279 mg, 43%). Rf = 0.47 (silica, CH2Cl2/MeOH, 85/15, v/v); m.p.: >180 oC 
(decomp.); [𝛼𝛼]𝐷𝐷20 = +1.75 (c 0.57, DMSO-d6); IR (neat, cm-1): 3485.2, 3327.3, 3169.7, 2952.1, 
1727.2, 1625.3, 1602.2, 1201.7; 1H NMR (400 MHz, DMSO-d6) δ 8.64 (s, 1H), 8.31 (d, J = 7.5 
Hz, 1H), 7.99 (s, 2H), 7.75 (d, J = 8.0 Hz, 2H), 7.72 – 7.60 (m, 3H), 7.47 (br s, 1H), 7.23 (d, J = 
8.0 Hz, 2H), 6.82 (d, J = 9.1 Hz, 2H), 6.63 (br s, 2H), 4.93 (s, 2H), 4.89 (s, 2H), 4.38 (ddd, J = 9.6, 
7.5, 5.3 Hz, 1H), 3.61 (s, 3H), 3.57 (s, 3H), 2.41 (t, J = 7.5 Hz, 2H), 2.17 – 1.79 (m, 2H); 13C NMR 
(101 MHz, DMSO-d6) δ 172.72, 172.54, 166.38, 162.83, 162.71, 155.18, 150.37, 149.36, 145.92, 
140.38, 134.39, 128.93, 125.66, 121.41, 121.10, 111.48, 54.47, 53.98, 51.82, 51.71, 51.35, 29.92, 
25.77; HRMS (ESI) m/z: calcd for C28H32BN8O7 [M+H]+ 603.2482, found 603.2508. 
 (4-((4-Boronobenzyl)((2,4-diaminopteridin-6-yl)methyl)amino)benzoyl)-L-glutamic acid 
(25). A solution of 24 (46 mg, 76 µmol) in 1 M aq. NaOH (2mL) was stirred for 5 min at 21 oC. 
The crude was directly purified by reversed-phase preparative HPLC to afford the title compound 
25 as a yellow solid (17 mg, 40%). m.p.: >245 oC (decomp.); [𝛼𝛼]𝐷𝐷20 = +7.8 (c 0.63, DMSO); IR 
(neat, cm-1): 3336.5, 3089.8, 1633.5, 602.7, 1502.8, 1394.2, 1364.9, 1337.0, 1202.5; 1H NMR (400 
MHz, DMSO-d6) δ 8.63 (s, 1H), 8.08 (d, J = 7.3 Hz, 1H), 8.01 (s, 2H), 7.73 (d,  
J = 7.9 Hz, 2H), 7.69 – 7.55 (m, 3H), 7.46 (br s, 1H), 7.22 (d, J = 7.9 Hz, 2H), 6.81 (d, J = 8.9 Hz, 
2H), 6.61 (br s, 2H), 4.91 (s, 2H), 4.88 (s, 2H), 4.32 (ddd, J = 9.7, 7.9, 5.1 Hz, 1H), 2.3 (t,  
J = 7.5, 2H), 2.02 – 1.78 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 174.0, 173.7, 166.2, 162.9, 
162.7, 155.2, 150.3, 149.4, 145.9, 140.4, 134.4, 128.8, 125.7, 121.5, 121.4, 111.5, 54.4, 54.0, 51.8, 
30.6, 26.2; HRMS (ESI) m/z: calcd for C26H28BN8O7 [M+H]+  575.2169, found 575.2187. 
Physicochemical and pharmacokinetic in vitro assays 
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Activation of prodrugs under oxidative conditions. To a mixture of DMSO (150 μL) and aq. PBS 
buffer (650 μL, pH 7.4) in a microcentrifuge tube (1.5 mL) placed in a thermomixer at 37 oC was 
added a solution of prodrug (50 μL, 1 mM in DMSO) followed by addition of internal standard 
solution (diclofenac, 50 μL, 1 mM in DMSO). The assay was initiated by addition of a solution of 
H2O2 in PBS (50 μL, 10 mM) followed by vortex mixing. The resulting mixture was incubated at 
37 oC in an Eppendorf Thermomixer C (1.5 mL, 1000 rpm) and samples were taken after 5, 15, 
30, 60, 90 min and 2, 3, and 4 h. Analysis of the percentage of remaining compound was performed 
using RP-UPLC-UV (λ= 306 nm). Further data points were collected for compounds 24 and 25, 
including 16, 24 and 48 h. A control experiment (no H2O2 addition but PBS) was performed in 
parallel. Every prodrug activation assay was carried out in triplicates.   
Activation of prodrugs under different H2O2 concentrations. To aq. PBS buffer (750 μL, pH 7.4) 
was added a solution of prodrug 17 or 25 (100 μL, 1 mM in DMSO) followed by addition of 
internal standard solution (diclofenac, 100 μL, 1 mM in DMSO). The assay was initiated by 
addition of a solution of H2O2 in PBS (50 μL, 10 - 5 – 1 – 0.5 – 0.25 mM) followed by vortex 
mixing. The resulting mixture was incubated at 37 oC in a Eppendorf Thermomixer C (1.5 mL, 
1000 rpm) and samples were taken after 5, 15, 30, 60, 90 min and 2, 4, 24 h (48 h for compound 
25). Analysis of the percentage of remaining compound was performed using RP-UPLC-UV (λ= 
306 nm). A control experiment (no H2O2 addition but PBS) was performed in parallel. Every 
prodrug activation assay was carried out in triplicates. 
Kinetic solubility. The kinetic solubility of prodrugs 11, 12, 13, 17, 24, and 25 was determined 
in a 1% DMSO in PBS solution at a concentration of 100 µM. A solution of test compound (10 
µL, 10 mM) was added to an microcentrifuge tube containing PBS (990 µL, pH 7.4), and the 
mixture was incubated at 37 °C for 20 hours in a Eppendorf Thermomixer C (1.5 mL, 1000 rpm). 
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After 20 h incubation, the samples were centrifuged at 5000 rpm (37 °C, 30 min) to pellet insoluble 
material. Aliquots (250 µL) of the supernatant were diluted in PBS (250 µL) and the concentration 
of dissolved compound was quantified by RP-UPLC-UV (λ= 306 nm) analysis. Solubility 
determinations were performed in triplicates.  
Chemical Stability pH 7.4. The chemical stability at pH 7.4 of compounds 17 and 25 was 
assessed using diclofenac as an internal standard. To 490 µL of a pre-warmed solution of 20 µM 
diclofenac in PBS (0.1% DMSO) was added 10 µL of a 1 mM DMSO solution of compound 17 
and 25 (in triplicates) and RP-UPLC-UV (λ= 306 nm) analysis was performed after 30 min, 1 h, 2 
h, 4 h, 8 h, 24 h, and 48 h. 
Simulated gastric and intestinal fluid stability. Simulated gastric fluid (SGF) was generated by 
preparing a solution of sodium chloride (0.20 g), concentrated HCl (0.70 mL), and pepsin (Sigma, 
P-7000, 0.32 g) in deionized water (95 mL) up to a 100 mL of final volume. Simulated instestinal 
fluid (SIF) was generated by preparing a solution of monobasic potassium phosphate (KH2PO4, 
0.68 g), 0.1 N aqueous sodium hydroxide (38 mL), and pancreatin (Sigma, P-1625, 1.0 g) in 
deionized water up to 100 mL of final volume. The pH of the solution was adjusted to 7.5 by 
addition of 1 N aqueous sodium hydroxide.75 To 990 μL of SGF or SIF was added a solution of 
prodrug 17 or 25 (10 μL, 10 mM in DMSO). The resulting mixture was incubated at 37 oC in a 
Eppendorf Thermomixer C (1.5 mL, 1000 rpm) and samples were taken (90 μL) after 0, 1, 2, 4, 
and 24 h. Diclofenac (10 μL, 1 mM in DMSO) was added to the taken samples as internal standard. 
Analysis of the percentage of remaining compound was performed using RP-UPLC-UV (λ= 306 
nm). A negative control experiment (no pepsin or pancreatin addition) was performed in parallel. 
Every assay was carried out in triplicates. 
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Human and mouse plasma stability. 2 mL of lyophilized plasma (Sigma, P9523 for human and 
P9275 for mouse plasma) were dissolved in 2 mL of milli-Q water. To an microcentrifuge tube 
containing 240 μL of pre-warmed PBS (37 oC) was added 250 µL of plasma. The mixture was 
shaken at 300 rpm in an Eppendorf Thermomixer C (1.5 mL, 300 rpm) for 10 min before the assay 
was started. A solution of test compound 17 and 25 in DMSO (1 mM, 10 μL) was added to the 
pre-warmed PBS/plasma mixture to a final concentration of 20 μM. Samples (50 µL) were taken 
after 30 min, 1h, 2h, 4h, 8h, 24h and 48h and added to 150 μL of ice-cold MeOH containing an 
internal standard (diclofenac, 10 µM). Procaine and dilizatem were used as positive controls for 
human and mouse plasma stability, respectively. The half-lives (t1/2) was determined using 
GraphPad Prism 6 software and calculated with the slope of the linear region of the plotted 
logarithm of remaining compound against time, assuming first order kinetics. 
Human and mice microsomal stability. The in vitro microsomal metabolism of compounds 17 
and 25 was evaluated in isolated liver microsomes (pooled, from CD-1 male mouse and from 
human male) at a concentration of 10 µM. A solution of liver microsomes (10 mg/mL, 25 µL) was 
added to an microcentrifuge tube containing 425 µL of PBS at 37 oC in an Eppendorf Thermomixer 
C (1.5 mL, 1000 rpm) and the mixture was shaken for 10 min before the actual assay was started. 
Then, a DMSO solution of test compound (5 μL, 1 mM) was added followed by an aq. solution of 
NADPH (25 μL) for initiation of the experiment. A negative (no NADPH) and a positive control 
experiments (verapamil and diphenhydramine for human and mouse, respectively) were carried 
out in parallel. Aliquots (50 µL) were removed after 0 min, 5 min, 10 min, 15 min, 30 min, 45 min, 
and 60 min (additional 120 min and 240 min time points for the mice study) and quenched 
immediately with 50 µL of ice-cold MeCN containing an internal standard (diclofenac 10 µM). 
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Samples were analysed by RP-UPLC-UV and half-lives calculated plotting the Ln [C] versus time, 
assuming first order kinetics using GraphPad Prism 6. 
Cellular Assays 
Materials. Dulbecco’s Phosphate buffer (D-PBS) was purchased from Sigma Aldrich (D8662, 
pH 7.4). DMEM (D5976, Sigma Aldrich) and RPMI (R8758, Sigma Aldrich) were supplemented 
with 10% foetal bovine serum (FBS, heat-inactivated, Fisher Scientific), penicillin at 100 
units/mL, and streptomycin at 100 mg/mL (all purchased from Sigma Aldrich). The CellTiter  
96 ® AQueous Non-Radioactive Cell Proliferation Assay was purchased from Promega (MTS, 
G5421). 
Cell Culture. The human breast cancer MCF-7 (Sigma) and human large cell lung cancer NCIH-
460 (ATTC) cell lines were cultured in a humidified, 5% CO2 atmosphere at 37 oC in Dulbecco´s 
Modified Eagle´s Medium (DMEM) (Sigma) or Roswell Park Memorial Institute medium (RPMI) 
1640 (Sigma) supplemented with 10% foetal bovine serum (FBS, heat-inactivated, Fisher 
Scientific) and 1% penicillin/streptomycin. Both cell lines were subcultured every 2-3 days. 
Pre-activation of compounds with H2O2. A 125 µM solution of tested compound was prepared 
in a 1.25 mM H2O2 in DMSO:PBS (1:1), placed in an microcentrifuge tube and shaken at 21 oC 
for 24 h at 1000 rpm in an Eppendorf Thermomixer C (1.5 mL). The activation was followed by 
RP-UPLC-MS (λ = 306 nm) after 0 min, 15 min, 1 h, 4 h, and 24 h. A negative control consisting 
of a 125 µM solution of compound in a mixture of DMSO:PBS (1:1) without H2O2 was run in 
parallel to the activation assay under the same conditions.  
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Evaluation of cell viability. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-te-trazolium (MTS) assay (Promega Biotech AB, Stockholm, Sweden ) was 
used to determine the in vitro antiproliferative effect of the compounds. This assay is based on the 
principle that cells have the ability to reduce MTS tetrazolium, while, when dead, they lose this 
ability. MCF-7 and NCI-H460 cells were cultured in 96-well plates at an initial density of 104 
cells/well (MCF-7) or 7x103 cells/well (NCI-H460) in their respective growth medium. After 24 
h incubation to allow cell attachment, the medium was removed and the cells were incubated in 
the presence or absence of pre-activated compounds at different concentrations. After 48 h 
incubation time, the MTS reagent was added to each well. The cells were further incubated for a 
period of time between 30-60 min at 37 ºC until colorimetric reaction was developed within the 
linear range and the absorbance of the samples was measured at 490 nm using a 96-well plate 
spectrophotometer (Victor 3 plate reader with Wallac 1420 Workstation vs 3.0 software).  
A control was used for each tested compound, where cells were incubated with DMEM or RPMI 
containing the equivalent concentration of DMSO (maximum of 0.4% v/v). Each concentration of 
tested compounds was done in triplicates. The final concentration of H2O2 in each well was always 
<10 μM (non-cytotoxic concentration in MCF-7 and NCI-H460 cell lines, determined with the 
described assay). The IC50 values were calculated using GraphPad Prism v6.0 (California, USA) 
as the concentration of the compounds required to cause 50% response compared to cells exposed 
to controls using a non-linear dose-response regression. 
Collagen type-II-induced arthritis in vivo efficacy and preliminary toxicity assay 
Animals: DBA/1J mice (male, 8‒9 weeks) were obtained from Janvier, France. The mice were 
maintained in the animal facility at Redoxis, Medicon Village, Lund, Sweden, where they were 
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acclimatized for approximately one week before initiation of the experiment. All animal 
experiments were approved by the local animal ethic committee Malmö/Lund, Sweden, under the 
license N165-15. 
Induction of disease: collagen induced arthritis (CIA) was induced by intradermal immunization 
with 100 µg of chicken type-II collagen (CII, Chondrex) in Complete Freund’s Adjuvant (CFA, 
Difco) on day -1 via subcutaneous injection approximately 0.5 cm from the base of the tail. On 
day 21 a boost injection was administered in the same way with 50 µg CII. One week after the 
second immunization, onset of disease started to be observed (day 26).  
Anti-arthritic effect of test compounds and health evaluation: mice were randomly divided in 5 
groups (n = 8 per group): group I (vehicle), group II (MTX, Sigma Aldrich, 7.0 mg/kg, i.p.), group 
III (AMT, Enzo Life Sciences, 6.8 mg/kg, i.p.), group IV (17, 9.7 mg/kg, i.p.), group V (25, 8.8 
mg/kg, i.p.). Vehicle or test compound (2% DMSO in PBS, Life Technologies, injection volume 
370 µL) were dosed daily by intraperitoneal injections for 14 days, starting at onset of disease (day 
27). Disease was evaluated three times per week in a blinded fashion, starting at day 18 until the 
end of the experiment (day 40). A macroscopic scoring system of the four limbs ranging from 0 to 
15 (1 point per swollen toe, 1 point per swollen foot knuckle, and 5 points for swollen ankle) was 
used, meaning a maximal score of 60 per mice. For humane and ethical reasons and restrictions, 
mice with scores exceeding 45 were euthanized. The general health of mice was evaluated three 
times per week after disease induction. As an indicator of general health, animal body weight was 
used.  
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